NVO Stock Price and Chart — NYSE:NVO — TradingView

Compare with Novo Nordisk A/S

Key facts today

Novo Nordisk (NOVO_B) said China GLP‑1 net sales fell 8% in 2025 and cut list prices for two GLP‑1 drugs citing stronger local competition.

Analyze the impact Analyze the impact

Key stats

Upcoming earnings

Company info

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Ideas

NVO | Weekly Structure | $48 Could Unlock the Bull Case Thesis: NVO has spent more than a month compressing inside my $44-$48 accumulation zone, around several important long-term technical levels. I believe this consolidation is becoming increasingly constructive. If $48 can break and then flip to support, I would consider the Bull Case active and expe

Novo Nordisk A/S (NVO) — Technical Analysis Weekly (1W) | Current price: ~$47.51 Market Structure NVO remains in a long-term bearish trend, clearly defined by the descending orange trendline from the ~$78 area. However, the current price action is becoming interesting because NVO is approaching a potential accumulation/reversal zone around

by IbrahimTarek

Novo Nordisk A/S Class B (NOVO_B) – Bearish Setup | Target: 287 Novo Nordisk A/S Class B (NOVO_B): Arc Cycle Analysis Overview: Based on Arc Cycle Analysis applied to the 2h chart, Novo Nordisk is interacting with the 0.786 Arc within the current Arc Cycle. Price remains centered around this Arc, indicating that directional confirmation has not yet been establi

by Mohamad_Gharib

Nothing has changed ; $NVO is on track for recovery!- Pills are expanding multiple geography - Technical addressable market is growing. - Revenue will have a snowball effect when it reaches masses. - Volume is compensating for the price reduction because of deal with Trump

Novo Nordisk – Bullish Setup | Target: 306.00 #44 NOVO_B Price Outlook: Novo Nordisk Holds Above 1 (100%) Support Arc | Potential Rebound Toward 306.00 Novo Nordisk A/S Class B (NOVO_B): Arc Cycle Analysis Overview: Based on Arc Cycle Analysis applied to the 30m chart, Novo Nordisk is interacting with the 1 (100%) Support Arc within the current

by Mohamad_Gharib

EW count suggests that Novo might be reversing My count is disproportionate and wave 3 in (3) is not the smallest only on log scale. However, there are chances that the stock has reversed its trend. Zigzag correction off the top might be done and I outlined a couple of leading diagonal scenarios that might play out. What I really like is wave

by evgenii_tr_tech

$NVO , Idea Weekly chart. A pharma giant at a crossroads. NVO lost over 70% from its 2024 peak. The GLP-1 narrative cracked, competition arrived, and the market repriced brutally. Now at $43, it sits just above two major demand zones. Two scenarios on the table: Scenario 1 (yellow) : Capitulation into the $

NVO: Bullish Pennant Breakout Unlocks $+70$ Macro Target ### **The Macro Picture** Following a strong rally into early **2026**, **Novo Nordisk A/S ( NYSE:NVO $)** entered a healthy, multi-month consolidation phase. During this time, the price formed a textbook **Bullish Pennant** pattern, systematically carving out a series of lower highs and higher lows

by TaxpayerTrades

Novo Nordisk (NVO) | 1D Technical Analysis Novo Nordisk is approaching a critical technical inflection point after spending months in a primary downtrend. The recent price action is forming a Falling Wedge directly beneath the long-term descending trendline—a pattern that often precedes a bullish reversal when confirmed by a breakout. Marke

by IbrahimTarek

Novo Nordisk (NOV)Novo Nordisk (NVO) reported strong first-quarter earnings on May 6, 2026, with sales jumping 32% to reach 96.8 billion Danish kroner (~$15.2 billion). Driven by soaring demand for its popular GLP-1 weight-loss and diabetes drugs like Wegovy and Ozempic, the company beat earnings estimates and rais

See all ideas

Technicals

Summarizing what the indicators are suggesting.

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

An aggregate view of professional's ratings.

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds

Maturity dateNov 20, 2045

Coupon4.00% (Fixed)

Maturity dateFeb 20, 2038

Coupon3.63% (Fixed)

Maturity dateMay 27, 2037

Coupon3.63% (Fixed)

Maturity dateFeb 20, 2035

Coupon3.38% (Fixed)

Maturity dateMay 21, 2034

Coupon3.38% (Fixed)

Maturity dateMay 27, 2033

Coupon3.13% (Fixed)

Maturity dateFeb 20, 2032

Coupon3.00% (Fixed)

Maturity dateJan 21, 2031

Coupon3.25% (Fixed)

Maturity dateAug 27, 2030

Coupon2.88% (Fixed)

Maturity dateFeb 20, 2029

Coupon2.50% (Fixed)

Maturity dateMar 31, 2030

Coupon1.38% (Fixed)

See all NVO bonds

ETFs holding the stock

Weight3.08%

Market value‪81.54 M‬

Weight0.29%

Market value‪56.33 M‬

Weight4.97%

Market value‪49.88 M‬

Weight1.67%

Market value‪33.87 M‬

Weight2.26%

Market value‪20.00 M‬

Weight4.51%

Market value‪10.96 M‬

Weight4.51%

Market value‪10.96 M‬

Weight4.51%

Market value‪10.96 M‬

Weight0.45%

Market value‪9.49 M‬

Weight0.76%

Market value‪8.71 M‬

Weight126.76%

Market value‪7.31 M‬

Explore more ETFs